AQST - Mitsubishi Tanabe and Aquestive Therapeutics sign supply deal for EXSERVAN

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics (AQST) announce a licensing and supply deal for the U.S. rights to commercialize EXSERVAN (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis ((ALS)).Mitsubishi will commercialize EXSERVAN in the U.S. and Aquestive will serve as the exclusive sole manufacturer and supplier for the product. Mitsubishi plans to make EXSERVAN available to patients in the middle of 2021.Under the terms of the deal, Aquestive will receive upfront consideration, milestone payments, royalties on net sales of EXSERVAN in the U.S., and will earn revenue pursuant to the exclusive supply agreement. The exact financial terms of the deal were not disclosed.

For further details see:

Mitsubishi Tanabe and Aquestive Therapeutics sign supply deal for EXSERVAN